首页   按分类浏览 期刊浏览 卷期浏览 β‐Adrenergic agonists, potent nonspecific inhibitors of circulatory shock in rats
β‐Adrenergic agonists, potent nonspecific inhibitors of circulatory shock in rats

 

作者: C. J. E. Niemegeers,   F. Awouters,   P. A. J. Janssen,  

 

期刊: Drug Development Research  (WILEY Available online 1985)
卷期: Volume 5, issue 3  

页码: 225-231

 

ISSN:0272-4391

 

年代: 1985

 

DOI:10.1002/ddr.430050305

 

出版商: Wiley Subscription Services, Inc., A Wiley Company

 

关键词: β‐adrenergic agonists;potassium cyanide antagonism;compound 48/80 antagonism;rats;circulatory shock

 

数据来源: WILEY

 

摘要:

AbstractThe activity of a series of nine β‐adrenergic agonists was studied in the potassium cyanide (KCN; 5.00 mg/kg i.v.) and the compound 48/80 (0.50 mg/kg i.v.) lethality tests in rats. All compounds were found active in both tests. The ED50 values in mg/kg for protection against KCN‐induced lethality were as follows: clenbuterol (0.0047), zinterol (0.0055), hexoprenaline (0.0093), fenoterol (0.012), isoproterenol (0.014), colterol (0.019), salbutamol (0.028), terbutaline (0.14), and metaproterenol (0.33). The obtained results illustrate that KCN antagonism in rats is a general property of β‐adrenergic agonists and that their potency is in agreement with previously reported data for β‐adrenergic stimulation. By increasing the dose levels, the protective activity of some of the compounds disappeared and LD50s at which lethality to KCN was restored could be calculated. The protective dose range, which is defined as the ratio of the LD50 and the ED50, greatly varies among the test compounds. Protection from compound 48/80 induced lethality was also obtained with all compounds. This protection occurred at higher dose levels than in the KCN test, but persisted at agonist doses that had lost protective effect against KCN. Protection from KCN‐induced lethality seems to be due to an increased tissue perfusion and to occur as long as myocardial activity is not markedly changed from normal by the t

 

点击下载:  PDF (421KB)



返 回